The infiormation in the press release is intended fior investors.
Isofol Medical AB (publ) publishes
year-end report, January - December 2025
GOTHENBURG, Sweden, February 18, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), ("Isofol" or the "Company"), announced today that the company's year-end report for January - December 2025 is now available on the company's website, https://www.isofolmedical.com.
CEO's comments
"As our clinical study ofi arfiolitixorin progresses, Isofiol has participated in several scientifiic congresses in the US and Europe, and we note a signifiicant interest in our drug candidate. While the fiield ofi cancer therapeutics is advancing rapidly, innovations in fiirst-line treatment fior metastatic colorectal cancer remain limited - positioning arfiolitixorin to fiill an important unmet need also in the fiuture. With each quarter, we move closer to our goal: to improve cancer treatment fior millions ofi patients while creating substantial value fior shareholders, employees, and society," says CEO Petter Segelman Lindqvist.
Fourth quarter, October - December 2025
Net revenue amounted to kSEK 0 (0)
The result for the period amounted to kSEK -12,777 (-13,102)
Earnings per share amounted to SEK -0.05 (-0.08)
Cash and cash equivalents on December 31 amounted to kSEK 126,990 (96,157)
January - December 2025
Net revenue amounted to kSEK 0 (0)
The result for the period amounted to kSEK -54,168 (-43,488)
Earnings per share amounted to SEK -0.25 (-0.27)
The Board of Directors proposes that no dividend will be paid for the 2025 financial year
Significant events during the fourth quarter
On October 16, Isofol announced that the company participated in the ESMO cancer congress in Berlin, where an abstract describing the study design of Isofol's ongoing clinical phase Ib/II study was presented as an ePoster.
On November 13, Isofol announced that the European Patent Office (EPO) has issued an "Intention to Grant" for a new product patent for the company's cancer drug candidate arfolitixorin. Patent protection is thus secured until 2043.
Significant events after the end of the period
On January 9, 2026, Isofol announced that the company participated in the ASCO-GI cancer meeting in the USA, where a TiP abstract (Trial in Progress) describing the study design of Isofol's ongoing phase Ib/II clinical study was presented.
For more information, please contact
Isofol Medical AB (publ)Petter Segelman Lindqvist, Chief Executive Officer E-mail: petter.s.lindqvist@isofolmedical.com Phone: +46 (0)739 60 12 56
Margareta Hagman, CFO
E-mail: margareta.hagman@isofolmedical.com Phone: +46 (0)738 73 34 18
The infiormation was submitted fior publication, through the agency ofi the contact person set out above, at 07:30 CET on February 18, 2026.
About Isofol
Isofol works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
https://www.isofolmedical.com
Isofol Medical AB (publ), Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden info@isofolmedical.com, www.isofolmedical.com, VAT no:SE556759806401, Place of registered office: Göteborg